Measles second dose vaccine utilization and associated factors among children aged 24–35 months in Sub-Saharan Africa, a multi-level analysis from recent DHS surveys

被引：0
作者：
Dagmawi Chilot
Daniel Gashaneh Belay
Kegnie Shitu
Yibeltal Yismaw Gela
Mihret Getnet
Bezawit Mulat
Atalay Goshu Muluneh
Mehari Woldemariam Merid
Desalegn Anmut Bitew
Adugnaw Zeleke Alem
机构：
[1] Addis Ababa University,College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT
[2] University of Gondar,Africa)
[3] University of Gondar,Department of Human Physiology, College of Medicine and Health Science, School of Medicine
[4] University of Gondar,Department of Human Anatomy, College of Medicine and Health Science, School of Medicine
[5] Institute of Public Health,Department of Health Education and Behavioral Science, College of Medicine and Health Science
[6] University of Gondar,Department of Epidemiology & Biostatistics, College of Medicine and Health Science
[7] Institute of Public Health,Department of Reproductive health, College of Medicine and Health Science
[8] University of Gondar,undefined
[9] Institute of Public Health,undefined
来源：
BMC Public Health | / 22卷
关键词：
Measles; Measles-containing vaccine doses 2; MCV2; Immunization; Vaccination; Children; Sub-Saharan Africa;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 183 条
  • [1] Estofolete CF(2020)Prevalence of measles antibodies in São José do Rio Preto, São Paulo, Brazil: a serological survey model Sci Rep 10 1-8
  • [2] Milhim BHGdA(2007)Seroprevalence of measles, mumps, rubella and varicella among staff of a hospital in Riyadh, Saudi Arabia J Egypt Public Health Assoc 82 283-97
  • [3] CCGd F(2006)Measles virus: cellular receptors, tropism and pathogenesis J Gen Virol 87 2767-79
  • [4] GCDd S(2004)The clinical significance of measles: a review J Infect Dis 189 4-16
  • [5] Augusto MT(2016)The immune response in measles: virus control, clearance and protective immunity Viruses 8 282-606
  • [6] Terzian ACB(2019)Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens Science 366 599-8
  • [7] Abbas M(2012)Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data The Lancet 379 2173-9
  • [8] Atwa M(2020)Progress toward regional measles elimination—worldwide, 2000–2019 Morb Mortal Wkly Rep 69 1700-9
  • [9] Emara A(2005)Public-health impact of accelerated measles control in the WHO African Region 2000–03 The Lancet 366 832-204
  • [10] Yanagi Y(2017)The geography of measles vaccination in the African Great Lakes region Nat Commun 8 1-8
12345678910